AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer

Exclusion Criteria

• •Has other malignancies within 5 years prior to enrollment.
• •Is currently participating in a study of an investigational agent or using an investigational device.
• •Has known active central nervous system (CNS) metastases.
• •Has an active autoimmune disease that has required systemic treatment in the past 2 years.
• •Has an active infection requiring systemic therapy.
• •Has known active Hepatitis B or Hepatitis C.
• •History of myocardial infarction, unstable angina, congestive heart failure within 12 months prior to enrollment.
• •Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
• •Has received a live virus vaccine within 30 days of the planned first dose of study therapy.
• •Has any concurrent medical condition that, in the opinion of the Investigator, would complicate or compromise compliance with the study or the well-being of the subject.